Wilson Sonsini Advises Recursion on Definitive Agreement with Exscientia

Client Highlights

August 9, 2024

On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.

The agreement brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform. The combined business is positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster, and at a lower cost relative to traditional drug discovery and development methods.

The Wilson Sonsini team that advised Recursion included:

Corporate / M&A
Patrick Schultheis
Robert Ishii
Remi Korenblit
Brendan Mahan
Nathan Robinson
Ross Davies
Kaleigh Hawkins-Schulz
James Foster
Ashley Schmidt
Ava Munson
Cindy West